Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...you are right!
12th Annual BIO CEO & Investor Conference
Presenting Companies
http://www.ceo.bio.org/opencms/ceo/2010/Companies/PresentingCompanies.html
The 12th Annual BIO CEO & Investor Conference
View the Presentation Schedule!
http://ceo.bio.org/opencms/ceo/2010/Companies/BIO_CEO_2010_Program_Schedule.pdf
...well stolen!
- at least you have mentioned me...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46082472
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46082498
February 8-9 / 12th Annual BIO®_CEO_&_Investor_Conference
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
February 8-9 / 12th Annual BIO®_CEO_&_Investor_Conference
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Twelfth Annual BIO® CEO & Investor Conference
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Twelfth Annual BIO® CEO & Investor Conference
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Electric car maker Tesla Motors plans IPO
says will hold initial public offering; no date set yet for stock sale
January 29, 2010, 6:56 pm EST
http://finance.yahoo.com/news/Electric-car-maker-Tesla-apf-2378239160.html?x=0&sec=topStories&pos=1&asset=&ccode=
NEW YORK (AP) -- Electric car manufacturer Tesla Motors Inc. said Friday it plans to sell stock to the public.
The company, based in Palo Alto, Calif., did not disclose in a filing with the Securities and Exchange Commission specifically how much it plans to raise though it listed $100 million as a placeholder figure. The actual amount it raises could be higher.
Tesla also did not give a date for when it plans to launch the IPO, nor did it say how many shares it would sell or at what price.
A Tesla IPO has been widely anticipated. The company has garnered attention for its high-end Roadster, an all-electric sports car that retails for $109,000.
The two-door Roadster is the only model Tesla currently sells, but the company plans to start selling a four-door sedan, the Model S, in 2012. The Model S is slated to go for $49,900 when including a federal tax credit. That car is designed to travel as far as 300 miles on a three- to five-hour charge.
The company has not been profitable. Since its founding in 2003, it has lost $236.4 million, according to its filing. During the first nine months of 2009, it lost $31.5 million. The company said it has $106.5 million in cash as of Sept. 30.
Tesla said it has sold 937 Roadsters as of Dec. 31. The company has 10 stores in U.S. and Europe and disclosed plans to double that by end of the year. The company said it hopes to have 50 stores "within the next several years.
Tesla disclosed some of its biggest stakeholders in its filing. CEO Elon Musk, 38, a co-founder of PayPal and chairman of spaceship developer Space Exploration Corp., is the biggest shareholder by far with more than 81 million shares in the company.
Venture capital and other investment firms make up the bulk of Tesla's other large investors. They include Blackstar Investco LLC, Al Wahada Capital Investment LLC and affiliates of VantagePoint Venture Partners and Valor Equity Partners.
To help it build the Model S, the Department of Energy agreed to extend Tesla a $465 million loan last June. That money came from a pool Congress set aside in 2007 to help automakers develop fuel-efficient technology. Ford Motor Co., Nissan Motor Co. and other carmakers have also received loans from the fund.
Tesla's loan could give the government a stake in the automaker when it goes public. According to the filing, the Energy Department received warrants to purchase more than 9 million shares of Tesla when the loan closed on Jan. 20.
David Minlow, president of the IPO research firm IPOfinancial.com, called Tesla's intent to go public a "warning shot across the bow" of the automotive industry. But he cautioned that the company is not yet making a profit and will have to show investors it can produce cars on a large scale.
"I don't believe that just the sex appeal of the product and the name that goes with it is going to automatically convert into blind optimism on the part of investors," Minlow said.
Several high profile investment banks are underwriting the offering, including Goldman Sachs & Co., Morgan Stanley, J.P. Morgan and Deutsche Bank Securities.
if history repeated itself then news is to be expected soon...
February 9, 2007:
http://www.stemcellinnovations.com/news/item0018.php?news
February 6, 2009:
http://www.medicalnewstoday.com/articles/138071.php
*****
January 13, 2010:
...these observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year..
http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL
IMO <ax>
SIGA on target, plus Bio-Matrix and Adventrx's plays
Written by Vinny Cassano
Friday, 29 January 2010 03:45
http://biomedreports.com/articles/most-popular/26751-siga-on-target-bio-matrix-and-advenx-plays.html
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced
Date : 01/29/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=41314106&symbol=KERX
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced
Date : 01/29/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=41314106&symbol=KERX
Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia to be Published in the February 1, 2010 Issue of Clinical Cancer Research
NEW YORK, Jan. 29 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research. Perifosine, the Company's oral PI3K/Akt pathway inhibitor is currently being investigated in a Phase 3 trial, under Special Protocol Assessment, for the treatment of Advanced Multiple Myeloma. Similar to Multiple Myeloma and Non-Hodgkin's Lymphoma, Waldenstrom's is a hematologic disease in which the cancer cells target the bone marrow. There are currently no drugs FDA approved for the treatment of Waldenstrom's
Dr. Irene Ghobrial, Assistant Professor of Medicine, Bing Center for Waldenstrom's Macroglobulinemia at Dana-Farber Cancer Institute, led the Phase 2 study in which thirty-seven patients were treated with perifosine 150 mg daily for 6 cycles. In this study, 41% of the patients had 3 or more lines of prior therapy and 78% had 2 or more prior lines of therapy. Such prior therapies include nucleoside analogues, bortezomib, alkylating agents and rituximab, which are not approved for, but are often used in the treatment of Waldenstrom's. The median % involvement of the bone marrow with lymphoplasmacytic cells was 70%, indicating advanced disease. Stable or responding patients were allowed to continue therapy until progression. Of the 37 patients, 4 achieved a partial response (11%), 9 achieved a minimal response (24%), and 20 showed stable disease (54%). Overall, 89% (33/37) of patients treated with single agent perifosine were reported to have stable disease or better, while 11% (4 patients) demonstrated progression. The median progression-free survival in the study was 12.6 months (90% C.I. (10.2, 22.7)), with a median overall survival of 26 months (90% C.I. (26 - upper limit not reached)). Perifosine was generally well-tolerated with gastrointestinal symptoms and fatigue reported as the most common adverse events related to therapy
Also described in the article are translational studies using gene expression profiling and immunohistochemistry on pre- versus post-treatment patient samples conducted by Dr. Ghobrial. Results showed that in the majority of samples tested, there was a significant reduction of phospho-GSK3/beta (downstream from Akt) using immunohistochemistry. Similarly, results demonstrated that perifosine significantly inhibited the expression of multiple members of the NF-kB family of genes, confirming previous in vitro studies showing activity of perifosine targeting this pathway
"Perifosine as a single agent holds great promise in the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia," commented Dr. Ghobrial, who continued, "Responses were durable and occurred rapidly. The progression-free survival of 12.6 months is considered long compared to other targeted agents used in a similar population such as bortezomib (Velcade®), where the median time to progression was reported at 7.9 months. We look forward to further evaluating perifosine's promise in this disease, either as a single agent or in combination with agents such as rituximab (Rituxan®) or bortezomib."
Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, remarked "We are very excited to see this single agent activity of perifosine, which further demonstrates its potential as a targeted agent. This Waldenstrom's data is of particular interest because, similar to multiple myeloma, Waldenstrom's is also a bone-marrow-based hematologic tumor. Moreover, Waldenstrom's represents an unmet medical need for which there are no approved drugs and therefore could potentially provide us with an additional registration strategy for perifosine. Finally, we wish to thank Dr. Ghobrial and her impressive team of investigators for their dedication to this Waldenstrom's program."
Perifosine is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), for the treatment of relapsed/refractory multiple myeloma, with Orphan Drug Status and Fast Track Designation granted
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico
About Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia is a distinct lymphoproliferative disorder characterized by bone marrow infiltration with lymphoplasmacytic cells, along with an IgM monoclonal gammopathy. Waldenstrom's affects an estimated 1,500 patients annually in the U.S. Despite advances in the therapy of Waldenstrom's, the disease remains incurable, thereby necessitating the development of novel therapeutics. There are no drugs currently FDA approved for Waldenstrom's, with nucleoside analogues, the proteasome inhibitor bortezomib (Velcade®), alkylating agents (chlorambucil) and rituximab (Rituxan®) often used to treat the disease
About KRX-0401 (Perifosine)
KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis
Keryx has been granted a Special Protocol Assessment (SPA) from the FDA for the Phase 3 study of perifosine in multiple myeloma. Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in multiple myeloma
About Keryx Biopharmaceuticals, Inc
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401, including, but not limited to, the indication of Waldenstrom's Macroglobulinemia; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only
KERYX CONTACT: Lauren Fischer Director, Investor Relations Keryx Biopharmaceuticals, Inc
Tel: 212.531.5962 E-mail:
DATASOURCE: Keryx Biopharmaceuticals, Inc
CONTACT: Lauren Fischer, Director, Investor Relations, Keryx
Biopharmaceuticals, Inc., +1-212-531-5962,
Web Site: http://www.keryx.com/
Genworth Financial Announces Fourth Quarter 2009 Results
/ Earnings Improvement Demonstrates Strategic Progress
28.01.2010 22:05
http://www.finanznachrichten.de/nachrichten-2010-01/16009420-genworth-financial-announces-fourth-quarter-2009-results-earnings-improvement-demonstrates-strategic-progress-008.htm
RICHMOND, Va., Jan. 28 /PRNewswire-FirstCall/ --
Genworth Financial, Inc. today reported results for the fourth quarter of 2009. Net income(1), before provision for noncontrolling interests, was $75 million, or $0.15 per diluted share, compared with a net loss of $321 million, or $0.74 per diluted share, in the fourth quarter of 2008. Net operating income(2), before provision for noncontrolling interests, for the fourth quarter of 2009 was $128 million, or $0.26 per diluted share, compared to a net operating loss of $207 million, or $0.48 per diluted share, in the fourth quarter of 2008.
Reflecting the company's reduction in ownership of Genworth MI Canada in the third quarter of 2009 from 100 percent to 57.5 percent in connection with an initial public offering (IPO) transaction, Genworth's net income available to Genworth's common stockholders was $40 million, or $0.08 per diluted share, in the fourth quarter of 2009. On this same basis, net operating income available to Genworth's common stockholders for the fourth quarter of 2009 was $94 million, or $0.19 per diluted share.
Genworth Financial Announces Fourth Quarter 2009 Results
/ Earnings Improvement Demonstrates Strategic Progress
28.01.2010 22:05
http://www.finanznachrichten.de/nachrichten-2010-01/16009420-genworth-financial-announces-fourth-quarter-2009-results-earnings-improvement-demonstrates-strategic-progress-008.htm
RICHMOND, Va., Jan. 28 /PRNewswire-FirstCall/ --
Genworth Financial, Inc. today reported results for the fourth quarter of 2009. Net income(1), before provision for noncontrolling interests, was $75 million, or $0.15 per diluted share, compared with a net loss of $321 million, or $0.74 per diluted share, in the fourth quarter of 2008. Net operating income(2), before provision for noncontrolling interests, for the fourth quarter of 2009 was $128 million, or $0.26 per diluted share, compared to a net operating loss of $207 million, or $0.48 per diluted share, in the fourth quarter of 2008.
Reflecting the company's reduction in ownership of Genworth MI Canada in the third quarter of 2009 from 100 percent to 57.5 percent in connection with an initial public offering (IPO) transaction, Genworth's net income available to Genworth's common stockholders was $40 million, or $0.08 per diluted share, in the fourth quarter of 2009. On this same basis, net operating income available to Genworth's common stockholders for the fourth quarter of 2009 was $94 million, or $0.19 per diluted share.
Amended Statement of Changes in Beneficial Ownership (4/A)
Date : 01/28/2010 @ 1:51PM
Source : Edgar (US Regulatory)
Stock : (ENCO)
http://ih.advfn.com/p.php?pid=nmona&cb=1264705616&article=41302147&symbol=N^ENCO
IBOX and Current report filing (8-K)
Date : 01/13/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : - (SCLL)
http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL
Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year.
Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year and these advances will enable us to pursue the application of our technology to drug discovery, liver disease and cancer. It is important to note that this technology is completely separate from standard human embryonic stem cells and comprises a unique and valuable intellectual property.
As a result of the shareholder vote that was held in August, the number of authorized shares was expanded to 20 billion. There are currently 2,844,387,312 shares issued and outstanding. The financing by Margie Chassman that was announced in conjunction with the vote has been completed. These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings. It is important to the Company to be as transparent as possible within the confines of this difficult financial environment and we are working diligently to achieve this.
This update contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as “expects”, “intends”, “believes”, “may”, “will” and “anticipates” to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company’s periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
Keryx / Aeterna Drug Shows Promise in Late-Stage Colon Cancer Patients
Written by Mike Havrilla
Wednesday, 27 January 2010 06:34
http://biomedreports.com/articles/most-popular/26434-keryx-aeterna-drug-shows-promise-in-late-stage-colon-cancer-patients.html
EMCORE Corporation Awarded Solar Panel Manufacturing Contract From ATK Space Systems
Jan 27, 2010 08:30 ET
http://www.marketwire.com/press-release/EMCORE-Corporation-Awarded-Solar-Panel-Manufacturing-Contract-From-ATK-Space-Systems-NASDAQ-emkr-1107820.htm
EMCORE Corporation Awarded Solar Panel Manufacturing Contract From ATK Space Systems
Jan 27, 2010 08:30 ET
http://www.marketwire.com/press-release/EMCORE-Corporation-Awarded-Solar-Panel-Manufacturing-Contract-From-ATK-Space-Systems-NASDAQ-emkr-1107820.htm
EMCORE Corporation Awarded Solar Panel Manufacturing Contract From ATK Space Systems
Contract Awarded for NASA's Orion Crew Exploration Vehicle (CEV) Project
ALBUQUERQUE, NM--(Marketwire - January 27, 2010) - EMCORE Corporation (NASDAQ: EMKR), a leading provider of compound semiconductor-based components, systems and subsystems for the fiber optic and solar power markets, announced today that the Company has been awarded a contract by ATK Space Systems of Goleta, California to manufacture, test, and deliver solar panels for ATK's UltraFlex™ solar arrays. These solar arrays will be used to power the Orion spacecraft being developed by Lockheed Martin Space Systems Company for NASA. The period of performance for this contract for the first two vehicles runs through 2013 and is valued in the range of $9-$11 million. The flight solar array system is expendable for each Orion mission and continuous production is expected to run through 2020 and beyond.
The Orion crew exploration vehicle (CEV) program will serve as NASA's next generation human space transportation system. This vehicle is intended to replace the current Space Shuttle and will provide human space flight systems capable of transferring astronauts to and from the International Space Station (ISS), the Moon and other destinations within the solar system. NASA expects to order multiple Orion Constellation vehicles over the next decade.
EMCORE's latest generation ZTJ triple-junction solar cells will be designed into the solar panels delivered to ATK Space Systems. With a sunlight-to-electricity conversion efficiency of 30%, the ZTJ solar cell is the highest performance space qualified multi-junction solar cell available in the industry world today. Production of the solar panels will take place at EMCORE's state-of-the-art manufacturing facilities located in Albuquerque, New Mexico.
"We are very excited to be using the EMCORE ZTJ triple junction solar cells in the ATK Ultraflex™ solar array design," said Dave Messner, Vice President and General Manager of ATK's Solar Array and Deployables site based in Goleta, California. "The ATK UltraFlex™ solar array design will be providing 14kW of power per shipset with superior performance characteristics and mission enabling features, including ultra-lightweight, high strength, high stiffness, and compact stowage volume. The EMCORE solution will enable ATK to provide the UltraFlex™ solar array configured for Orion so that it will provide over twenty times the strength and ten times the stiffness of our conventional rigid panel solar arrays, at less than one-third the weight."
Christopher Larocca, Chief Operating Officer of EMCORE, stated, "This CEV program represents a significant award for EMCORE. The solar panels for this program will provide the critical power needs required for the next phase of NASA's human exploration program. We have enjoyed a long-term relationship with ATK Space Systems and look forward to partnering with them on this exciting program."
EMCORE is the world's largest manufacturer of highly efficient radiation hard solar cells for space power applications. With a beginning-of-life (BOL) conversion efficiency of 30%, EMCORE's industry leading multi-junction solar cells can provide the highest power to interplanetary spacecraft and earth orbiting satellites.
About EMCORE:
EMCORE Corporation offers a broad portfolio of compound semiconductor-based products for the broadband, fiber optic, satellite and solar power markets. EMCORE's Fiber Optic segment offers optical components, subsystems and systems for high speed data and telecommunications networks, cable television (CATV) and fiber-to-the-premises (FTTP). EMCORE's Photovoltaic segment provides products for both satellite and terrestrial applications. For satellite applications, EMCORE offers high efficiency Gallium Arsenide (GaAs) solar cells, Covered Interconnect Cells (CICs) and panels. For terrestrial applications, EMCORE is adapting its high-efficiency GaAs solar cells for use in solar concentrator systems. For further information about EMCORE, visit http://www.emcore.com.
About ATK:
ATK is an industry leader in solar array systems-engineering competencies. It offers a broad range of technologies, skills and products, and a proven production and test capability for solar array systems. To date the company has delivered over 70 solar array wing systems.
ATK is an advanced weapon and space systems company with annual revenues in excess of $4.1 billion that employs more than 17,000 people in 21 states. News and information can be found on the Internet at http://www.atk.com.
Forward-looking statements:
The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, any statement or implication that the products described in this press release that the contract described will be successfully completed. Such forward-looking statements involve risks and uncertainties that, if realized, could materially impair the Company's results of operations, business, and financial condition. These risks and uncertainties include, but are not limited to, (a) the successful completion of all of ATK's own contract relating to this project (which can be terminated for convenience, as can EMCORE's contract and the contracts of all parties involved in the project) and (b) factors discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The forward-looking statements contained in this news release are made as of the date hereof and EMCORE does not assume any obligation to update the reasons why actual results could differ materially from those projected in the forward-looking statements.
Purposes of Amendment
http://ih.advfn.com/p.php?pid=nmona&cb=1264440958&article=41244053&symbol=N^NEXM
In the past, the Company has funded its operations primarily through the sale of equity and issuance of convertible debt and expects to continue to need additional external financing to provide additional working capital and to continue the development of its product candidates. As of the Record Date, we had 106,928,753 shares of Common Stock outstanding and 12,408,048 shares of Common Stock reserved for issuance, out of the 120,000,000 authorized shares of Common Stock. Accordingly, the Company has essentially no additional shares of authorized Common Stock available for future issuance.
The Board of Directors believes the adoption of the foregoing amendment is both necessary and advisable. Without additional authorized shares of Common Stock, the Company will be unable, or severely limited in its ability, to do any of the following:
· raise additional capital through the sale of Common Stock;
· use Common Stock as consideration in making acquisitions of complementary products, companies or technologies;
· grant future equity awards to employees, officers and directors as needed to attract and retain their services; and
· conserve cash and use Common Stock as consideration for other purposes, such as to service indebtedness of the Company.
At the present time, the Company has no commitments to issue shares of Common Stock upon the approval of this proposal. However, the Board considers it necessary to have additional authorized shares to be able to take action with respect to these matters as may be deemed appropriate from time to time. Authorized but unissued shares of the Common Stock may be issued for such purposes and for such consideration as the Board of Directors may determine to be appropriate without further authority from the Stockholders, subject to other limits that may be imposed under applicable law, stock exchange (including NASDAQ) policies, and applicable limits under equity incentive plans. To the extent that the Company wishes to issue shares in an amount that is beyond the limits permitted by any of these laws, rules or regulations, the Company would first seek stockholder approval of any such issuance.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45861875
NEWS pending ??
Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Therapy
Date : 01/26/2010 @ 9:00AM
Source : PR Newswire
Stock : (CXM)
http://ih.advfn.com/p.php?pid=nmona&article=41259233&symbol=CXM
Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Therapy
Date : 01/26/2010 @ 9:00AM
Source : PR Newswire
Stock : (CXM)
http://ih.advfn.com/p.php?pid=nmona&article=41259233&symbol=CXM
SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ --
Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx(TM) (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease. The update was presented by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer at the annual 2010 Cell & Gene Therapy Forum in Washington, D.C. on January 25, 2010. An investor presentation that includes material from Dr. Rubanyi's presentation is now available on Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
Cardium Biologics reported on the following findings and plans:
(1) As previously announced, based on an agreement with the FDA, Generx would be re-formulated to increase its shelf life, and further formulation enhancements are expected to allow for storage using a standard freezer (rather than at -70 degrees C), and potentially a lyophilized version for refrigerated storage
(2) Based on clinical and pre-clinical findings, angiogenic therapy appears to lead to long-term functional improvements in cardiac microvascular circulation, and Cardium believes that cardiac perfusion (as measured by SPECT) appears to be an important efficacy endpoint to consider that is now supported by a 10-year study of the cardio-protective nature of collateral circulation (Meier et al. Circulation 2007; 116:975-83)
(3) Recent preclinical data developed by the Company under an SBIR grant indicate that localized ischemia can significantly increase Ad5 transfection in the heart in association with intracoronary infusion therapy, suggesting that cardiac stimulation (using e.g. dobutamine which is routinely administered to patients) in association with administration of Generx has the potential to dramatically enhance the therapeutic effect at a given dose
(4) In order to incorporate these enhanced formulations and perspectives and also expand the clinical database supporting the potential commercialization of Generx, the Company is considering clinical and commercialization pathways for Generx in developing nations that often have very limited access to surgical approaches such as angioplasty, stenting or coronary artery bypass (which are available to patients in industrialized nations but at costs reaching $80,000 to $100,000 per procedure over a five year period). The U.S. and European clinical studies of Generx have collectively established an extensive database supporting the safety of this product candidate, even in patients with severe forms of chronic coronary artery disease. Successful application of this therapy as "front-line care" would be expected to lead to commercialization pathways in many developing markets for which surgical and other relatively expensive approaches are either unavailable or limited by already over-burdened health care systems. In addition, information gained with these new applications would be expected to be useful to support broadened commercialization pathways in the U.S. and other developed markets
"There has been significant progress in the care and treatment of patients with cardiovascular disease in the industrialized world, although at considerable and increasing expense. While heart disease remains a very serious problem in the U.S. and Europe, incidence is rapidly increasing in large parts of the newly-industrializing world such as China, India and Russia, as well as in the Middle East and Latin America. In many countries, healthcare systems are unable to provide wide access to relatively expensive procedures such as coronary angioplasty, stenting, or cardiac bypass surgery. Based on data indicating that the Generx product candidate appears to safe and has the potential to substantially increase coronary blood flow in the context of heart disease - coupled with recent findings that improvements in collateral circulation are associated with long-term benefits, including reduced mortality as reported in a 10-year study published in Circulation - we believe that this product candidate could be developed as a front-line therapy for coronary artery disease. Additional data gained in parallel studies, which would be expected to be conducted in collaboration with specific regional development partners, would also be expected to support an expanded U.S. registration dossier by providing additional safety data and potentially alternative efficacy measures," stated Christopher J. Reinhard, Cardium Chairman and Chief Executive Officer
Mechanism of Action Study: Generx Improves Blood Flow via Increased Collateral Circulation in Ischemic Heart Tissue
Reported in Journal of American College of Cardiology
Positive results supporting the proposed mechanism of action of Generx in improving blood flow within ischemic heart tissue were published in JACC, A Randomized, Double-Blind, Placebo-Controlled Trial of Ad5FGF-4 Gene Therapy and its Effect on Myocardial Perfusion in Patients with Stable Angina (Grines et al., J Am Coll Cardiol 2003; 42:1339-47). The results of the study showed improvements in myocardial perfusion (blood flow) in the ischemic region of the hearts of both men and women following a single intracoronary infusion of Generx. Increases in blood flow within the ischemic regions of the heart under the conditions studied (i.e., adenosine infusion) are believed to be due to the formation of new collateral blood vessels capable of providing additional blood flow capacity under stress. Generx was well tolerated in the study of 52 patients (88% men and 22% women) with reversible ischemia of >9%, with no adverse sequelae. As noted in the publication, the mean change observed in Generx-treated patients was a 4.2% absolute reduction (which represents a 20% relative reduction) in the reversible perfusion defect size from baseline at eight weeks
...something is cooking !
(HOD) $0.68
Purposes of Amendment
http://ih.advfn.com/p.php?pid=nmona&cb=1264440958&article=41244053&symbol=N^NEXM
In the past, the Company has funded its operations primarily through the sale of equity and issuance of convertible debt and expects to continue to need additional external financing to provide additional working capital and to continue the development of its product candidates. As of the Record Date, we had 106,928,753 shares of Common Stock outstanding and 12,408,048 shares of Common Stock reserved for issuance, out of the 120,000,000 authorized shares of Common Stock. Accordingly, the Company has essentially no additional shares of authorized Common Stock available for future issuance.
The Board of Directors believes the adoption of the foregoing amendment is both necessary and advisable. Without additional authorized shares of Common Stock, the Company will be unable, or severely limited in its ability, to do any of the following:
· raise additional capital through the sale of Common Stock;
· use Common Stock as consideration in making acquisitions of complementary products, companies or technologies;
· grant future equity awards to employees, officers and directors as needed to attract and retain their services; and
· conserve cash and use Common Stock as consideration for other purposes, such as to service indebtedness of the Company.
At the present time, the Company has no commitments to issue shares of Common Stock upon the approval of this proposal. However, the Board considers it necessary to have additional authorized shares to be able to take action with respect to these matters as may be deemed appropriate from time to time. Authorized but unissued shares of the Common Stock may be issued for such purposes and for such consideration as the Board of Directors may determine to be appropriate without further authority from the Stockholders, subject to other limits that may be imposed under applicable law, stock exchange (including NASDAQ) policies, and applicable limits under equity incentive plans. To the extent that the Company wishes to issue shares in an amount that is beyond the limits permitted by any of these laws, rules or regulations, the Company would first seek stockholder approval of any such issuance.
- Proxy Statement (definitive) (DEF 14A)
Date : 01/25/2010 @ 6:02AM
Source : Edgar (US Regulatory)
Stock : (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1264436683&article=41244053&symbol=N^NEXM
NEXMED, INC.
6330 Nancy Ridge Drive, Suite 103
San Diego, California, 92121
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Our Stockholders:
Notice is hereby given to the stockholders of NexMed, Inc. (the Company) that a Special Meeting of Stockholders of the Company (the Special Meeting) will be held on Tuesday, March 2, 2010 at 10 :00 a.m., local time, at the Company’s offices located at 6330 Nancy Ridge Drive, Suite 103, San Diego, California, for the following purposes:
(1)
To consider and vote upon a proposal to approve and adopt an amendment to the Company’s Amended and Restated Articles of Incorporation to increase the number of shares of Common Stock authorized for issuance by the Company from 120,000,000 to 270,000,000 shares.
(2)
To transact such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting To Be Held on March 2, 2010 . The enclosed Proxy Statement includes information relating to the above proposals. We encourage you to review all of the important information contained in the proxy materials before voting. Our proxy materials (which include the proxy statement attached to this notice and form of proxy card) are available to you via the internet at http://www.ir-site.com/nexmed/secfilings.html.
Stockholders may complete their proxy and authorize their vote by proxy over the Internet at www.proxyvote.com or by telephone at (800) 690-6903. Stockholders who complete their proxy electronically or by telephone do not need to return a proxy card. Stockholders may authorize their vote by proxy by mail by completing and returning the enclosed proxy card.
All stockholders of record of the Company's common stock, par value $0.001 per share (the Common Stock) at the close of business on January 21, 2010 are entitled to notice of and to vote at the Special Meeting or any adjournment or postponement thereof. A majority of the outstanding shares of Common Stock of the Company entitled to vote, represented either in person or by proxy, is required for a quorum.
By Order of the Board of Directors
/s/ Mark Westgate
Mark Westgate
Assistant Secretary
January 29, 2010
San Diego, California
THE BOARD OF DIRECTORS APPRECIATES AND ENCOURAGES YOUR PARTICIPATION IN THE COMPANY'S SPECIAL MEETING. WHETHER OR NOT YOU PLAN TO ATTEND THE SPECIAL MEETING, IT IS IMPORTANT THAT YOUR SHARES BE REPRESENTED. ACCORDINGLY, PLEASE SIGN, DATE AND PROMPTLY RETURN THE ENCLOSED PROXY CARD BY MAIL IN THE POSTAGE-PAID ENVELOPE PROVIDED, OR VOTE THESE SHARES BY TELEPHONE AT (800) 690-6903 OR BY INTERNET AT WWW.PROXYVOTE.COM. IF YOU ATTEND THE SPECIAL MEETING, YOU MAY REVOKE YOUR PROXY IF YOU WISH BY VOTING YOUR SHARES IN PERSON. YOUR PROXY IS REVOCABLE IN ACCORDANCE WITH THE PROCEDURES SET FORTH IN THE ACCOMPANYING PROXY STATEMENT.
---
As of the Record Date, there were 106,928,753 shares of Common Stock outstanding.
---
Purposes of Amendment
In the past, the Company has funded its operations primarily through the sale of equity and issuance of convertible debt and expects to continue to need additional external financing to provide additional working capital and to continue the development of its product candidates. As of the Record Date, we had 106,928,753 shares of Common Stock outstanding and 12,408,048 shares of Common Stock reserved for issuance, out of the 120,000,000 authorized shares of Common Stock. Accordingly, the Company has essentially no additional shares of authorized Common Stock available for future issuance.
The Board of Directors believes the adoption of the foregoing amendment is both necessary and advisable. Without additional authorized shares of Common Stock, the Company will be unable, or severely limited in its ability, to do any of the following:
·
raise additional capital through the sale of Common Stock;
·
use Common Stock as consideration in making acquisitions of complementary products, companies or technologies;
·
grant future equity awards to employees, officers and directors as needed to attract and retain their services; and
·
conserve cash and use Common Stock as consideration for other purposes, such as to service indebtedness of the Company.
At the present time, the Company has no commitments to issue shares of Common Stock upon the approval of this proposal. However, the Board considers it necessary to have additional authorized shares to be able to take action with respect to these matters as may be deemed appropriate from time to time. Authorized but unissued shares of the Common Stock may be issued for such purposes and for such consideration as the Board of Directors may determine to be appropriate without further authority from the Stockholders, subject to other limits that may be imposed under applicable law, stock exchange (including NASDAQ) policies, and applicable limits under equity incentive plans. To the extent that the Company wishes to issue shares in an amount that is beyond the limits permitted by any of these laws, rules or regulations, the Company would first seek stockholder approval of any such issuance.
...
Keryx cancer drug improves survival in mid-stage trial
25.01.2010 15:41
http://www.finanznachrichten.de/nachrichten-2010-01/15971573-update-1-keryx-cancer-drug-improves-survival-in-mid-stage-trial-020.htm
UPDATE 1-Keryx cancer drug improves survival in mid-stage trial
* Says drug shows more than 60 pct improvement in survival
* Mid-stage data also show better time to progression
* Shares rise 13 pct in premarket trade
Jan 25 (Reuters) - Keryx Biopharmaceuticals Inc said a mid-stage trial showed its colon cancer drug improved overall survival in heavily pre-treated patients with advanced metastatic colon cancer, as compared with a dummy drug, sending its shares up 13 percent in premarket trade.
The study enrolled a total of 38 patients, who were either given the drug KRX-0401, or perifosine, in combination with a chemotherapy drug capecitabine, or just capecitabine in combination with a dummy drug. Patients receiving KRX-0401 showed a greater than 60 percent improvement in overall survival and also demonstrated statistically significant advantage for time to progression, the company said in a statement.
However, the patients on the drug showed a higher incidence of adverse events like anemia and hand-foot syndrome as compared with those on the dummy drug.
'We are eager to finalize the design of a Phase 3 protocol in metastatic colorectal cancer within the next 3 months, in consultation with the FDA, and to commence the Phase 3 study as soon as practicable thereafter,' Chief Executive Ron Bentsur said in a statement. Perifosine is currently being tested in another late-stage trial for the treatment of relapsed/refractory multiple myeloma.
Shares of the company were up 13 percent to $3.11 in premarket trade. They closed at $2.74 Friday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Ratul Ray Chaudhuri) Keywords: KERYX/
(esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
Conference Call to Discuss Data to be Held on Thursday, January 28th at 9am EST
Monday January 25, 2010, 8:30 am
http://finance.yahoo.com/news/Keryx-Reports-Statistically-prnews-2783803.html?x=0&.v=1
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
Conference Call to Discuss Data to be Held on Thursday, January 28th at 9am EST
Monday January 25, 2010, 8:30 am
http://finance.yahoo.com/news/Keryx-Reports-Statistically-prnews-2783803.html?x=0&.v=1
NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
Date : 01/25/2010 @ 8:00AM
Source : PR Newswire
Stock : (NVAX)
http://ih.advfn.com/p.php?pid=nmona&article=41241607&symbol=NVAX
Obama facing huge economic challenges ahead
Obama under pressure to produce jobs but faces daunting economic and political challenges
Sunday January 24, 2010, 12:00 am EST
http://finance.yahoo.com/news/Obama-facing-huge-economic-apf-3470170550.html?x=0&sec=topStories&pos=1&asset=&ccode=#15589869428587522705
12th Annual BIO CEO & Investor Conference
An International Biotechnology Investor Conference Featuring Established & Emerging Public Companies
February 8-9, 2010
Waldorf-Astoria
New York City
Presenting Companies
http://ceo.bio.org/opencms/ceo/2010/Companies/PresentingCompanies.html
Randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1945
Sub-category:
Multidisciplinary Treatment
Category:
Cancers of the Colon and Rectum
Meeting:
2010 Gastrointestinal Cancers Symposium
Session Type and Session Title:
General Poster Session C: Cancers of the Colon and Rectum
Abstract No:
447
Author(s):
J. C. Bendell, D. A. Richards, S. J. Vukelja, L. T. Campos, C. T. Hagenstad, J. P. Letzer, J. J. Nemunaitis; Sarah Cannon Research Institute, Nashville, TN; US Oncology Research, Tyler, TX; Tyler Cancer Center, Tyler, TX; Onc Consult PA, Houston, TX; Suburban Hem and Onc, Lawrenceville, GA; Kalamazoo Hematology and Oncology, Kalamazoo, MI; Mary Crowley Cancer Research Center, Dallas, TX
Abstract:
Background: Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies different signal transduction pathways, including AKT, MAPK, and JNK. We previously reported initial results of a phase II randomized study of P + capecitabine (P-CAP) vs. CAP plus placebo (CAP), which demonstrated encouraging safety and clinical activity in 35 evaluable patients (pts) with advanced mCRC. We now report updated safety, overall response rate (ORR), time to progression (TTP), and overall survival (OS) for the 35 evaluable pts. Methods: Pts with second- or third-line mCRC, no previous CAP. Normal organ/marrow function required. Pts were randomized to P-CAP (P 50 mg PO QD + CAP 825 mg/m2 PO BID d1-14, 3 wk cycles) or CAP plus placebo. Results: 38 pts were randomized. Median age 67 (range 32-83); 61% male. Median prior Rx = 2 (range 1- 5). Prior Rx of P-CAP arm vs. CAP arm was as follows: FOLFIRI (90% vs. 93%); FOLFOX (75% vs. 73%); bevacizumab (75% vs. 80%); EGFR (45% vs. 60%); progressed on prior 5-FU-based Rx (70% vs. 73%). 35/38 pts were evaluable for response; 37/38 for toxicity. One pt refractory to 5-FU had a PR on P-CAP. CAP pt with PR was not 5-FU-refractory. Median OS for P-CAP vs. CAP is 24.3 vs. 16.3 mo (p = 0.1348) or 49% benefit on P-CAP. Median TTP and OS for refractory 5-FU pts (P-CAP vs. CAP): 18 vs. 10.3 wks (p = 0.0188); 24.3 vs. 11.7 mo (p = 0.0346). Most frequent G1/2 AE's (P-CAP vs. CAP): diarrhea (65% vs. 29%), nausea (45% vs. 29%), fatigue (45% vs. 35%), hand/foot syndrome (25% vs. 24%). Most frequent G3/4 AE's: hand/foot syndrome (25% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 12%). Conclusions: P-CAP is a well-tolerated regimen that has promising activity over CAP as second- or third-line therapy for patients with metastatic colorectal cancer. P-CAP also shows potential activity in 5-FU-refractory pts. A randomized phase III trial of P-CAP vs. CAP is planned for refractory colorectal cancer patients.
...
Randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1945
Sub-category:
Multidisciplinary Treatment
Category:
Cancers of the Colon and Rectum
Meeting:
2010 Gastrointestinal Cancers Symposium
Session Type and Session Title:
General Poster Session C: Cancers of the Colon and Rectum
Abstract No:
447
Author(s):
J. C. Bendell, D. A. Richards, S. J. Vukelja, L. T. Campos, C. T. Hagenstad, J. P. Letzer, J. J. Nemunaitis; Sarah Cannon Research Institute, Nashville, TN; US Oncology Research, Tyler, TX; Tyler Cancer Center, Tyler, TX; Onc Consult PA, Houston, TX; Suburban Hem and Onc, Lawrenceville, GA; Kalamazoo Hematology and Oncology, Kalamazoo, MI; Mary Crowley Cancer Research Center, Dallas, TX
Abstract:
Background: Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies different signal transduction pathways, including AKT, MAPK, and JNK. We previously reported initial results of a phase II randomized study of P + capecitabine (P-CAP) vs. CAP plus placebo (CAP), which demonstrated encouraging safety and clinical activity in 35 evaluable patients (pts) with advanced mCRC. We now report updated safety, overall response rate (ORR), time to progression (TTP), and overall survival (OS) for the 35 evaluable pts. Methods: Pts with second- or third-line mCRC, no previous CAP. Normal organ/marrow function required. Pts were randomized to P-CAP (P 50 mg PO QD + CAP 825 mg/m2 PO BID d1-14, 3 wk cycles) or CAP plus placebo. Results: 38 pts were randomized. Median age 67 (range 32-83); 61% male. Median prior Rx = 2 (range 1- 5). Prior Rx of P-CAP arm vs. CAP arm was as follows: FOLFIRI (90% vs. 93%); FOLFOX (75% vs. 73%); bevacizumab (75% vs. 80%); EGFR (45% vs. 60%); progressed on prior 5-FU-based Rx (70% vs. 73%). 35/38 pts were evaluable for response; 37/38 for toxicity. One pt refractory to 5-FU had a PR on P-CAP. CAP pt with PR was not 5-FU-refractory. Median OS for P-CAP vs. CAP is 24.3 vs. 16.3 mo (p = 0.1348) or 49% benefit on P-CAP. Median TTP and OS for refractory 5-FU pts (P-CAP vs. CAP): 18 vs. 10.3 wks (p = 0.0188); 24.3 vs. 11.7 mo (p = 0.0346). Most frequent G1/2 AE's (P-CAP vs. CAP): diarrhea (65% vs. 29%), nausea (45% vs. 29%), fatigue (45% vs. 35%), hand/foot syndrome (25% vs. 24%). Most frequent G3/4 AE's: hand/foot syndrome (25% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 12%). Conclusions: P-CAP is a well-tolerated regimen that has promising activity over CAP as second- or third-line therapy for patients with metastatic colorectal cancer. P-CAP also shows potential activity in 5-FU-refractory pts. A randomized phase III trial of P-CAP vs. CAP is planned for refractory colorectal cancer patients.
...
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium
Updated Results from Phase 2 Clinical Trial of KRX-0401 in Combination with Capecitabine for the treatment of Metastatic Colon Cancer to be Presented on Sunday, January 24, 2010
Thursday January 21, 2010, 8:30 am EST
http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-893823691.html?x=0&.v=1
...
?? can we get a <CXM> annotated Chart ??
http://investorshub.advfn.com/boards/board.aspx?board_id=16154
thanks for your advice!
ax
** WAMUQ Annotated Chart **
Posted by: ClayTrader
Date: Friday, January 22, 2010 6:02:52 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45804580